Last reviewed · How we verify
REG1
At a glance
| Generic name | REG1 |
|---|---|
| Sponsor | Regado Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (PHASE1, PHASE2)
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (PHASE1, PHASE2)
- A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (PHASE3)
- Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI (PHASE2)
- A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome (PHASE2)
- Safety and Dosing Evaluation of REG1 Anticoagulation System (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REG1 CI brief — competitive landscape report
- REG1 updates RSS · CI watch RSS
- Regado Biosciences, Inc. portfolio CI